[Skip to Content]
[Skip to Content Landing]
July 6, 1994

Nicotine Patch for Smoking Cessation-Reply

Author Affiliations

Mayo Clinic Rochester, Minn

JAMA. 1994;272(1):32. doi:10.1001/jama.1994.03520010042029

In Reply.  —Dr Lahad's letter discusses the possible role that univariate disparities in various baseline factors might have in explaining the difference in smoking cessation rates in our double-blind, placebo-controlled, randomized trial. Adjustment for such factors is more critical in epidemiologic retrospective, nonrandomized studies where various biases may distort the findings.Two points are noteworthy. First, our results showing the efficacy of transdermal nicotine replacement therapy are consistent with other randomized trials where, in general, active treatment results in a doubling of the smoking cessation rate.1-3 Second, using logistic regression, we reanalyzed the 8-week and 1-year cessation rates, adjusting for the six baseline variables mentioned by Dr Lahad (employed, depressed or "down," previously treated for depression, pack-years of cigarette smoking, serum cotinine level, and baseline withdrawal symptom score). Assignment to active patch treatment was still a significant predictor of cessation adjustment for these after 8 weeks (two-tail P<.001)

First Page Preview View Large
First page PDF preview
First page PDF preview